InSilico Medicine Cayman TopCo - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
IMDCY Over the counter 2836 insilico.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for InSilico Medicine Cayman TopCo

In-Silico Drug Discovery Market Report Now Available: Capitalize on AI-led R&D disruption as revenue surges from $3.3B to $6B by 2030; benchmark Certara, Insilico Medicine, Isomorphic Labs, Exscientia and BenevolentAI to secure share. - Sep 30th, 2026 7:32 am
Breaking the Safety Barrier: Insilico Medicine Nominates ISM1354, the Next-Generation Small Molecule GIPR Antagonist - Sep 29th, 2026 11:57 pm
Lilly’s latest China drug deal; Immunovant’s setback in lupus - Sep 24th, 2026 8:14 am
Capitalize on AI’s Drug Discovery Disruption: Benchmark NVIDIA, Schrödinger, Recursion, Insilico Medicine and Exscientia to Secure R&D ROI and Competitive Advantage Through 2030 - Sep 23rd, 2026 2:07 am
Insilico Medicine (SEHK:3696) Takes Its AI Discovered Drug Into Phase III Trials - Sep 19th, 2026 12:08 pm
Insilico Medicine’s Alex Zhavoronkov bets China and AI can deliver the drug industry’s next breakthrough - Sep 18th, 2026 1:00 am
Insilico Medicine Opens AI Longevity Discovery Toolkit to Researchers Worldwide in Cell Cover Study - Sep 17th, 2026 9:21 am
Insilico Medicine Doses First Patient in GENESIS-IPF-3, the World's First Phase III Trial of a Generative AI-Driven Innovative Drug - Sep 9th, 2026 6:30 pm